Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep873 | Developmental endocrinology | ECE2017

Can dehydroepiandrosterone-sulphate be a new diagnostic parameter in male patients with idiopathic hypogonadotropic hypogonadism?

Cadirci Kenan , Carlioglu Ayse , Durmaz Senay

DHEA and its sulphate derivative DHEA-sulphate (DHEA-s) are major androgen hormones of adrenal origin. The purpose of this study was to investigate DHEA-s levels in male patients with idiopathic hypogonadotropic hypogonadism (IHH) and to determine whether DHEA-s levels are a useful marker in the diagnosis of hypogonadotropic hypogonadism. 91 subjects, 31 male patients diagnosed with IHH (mean age 19.7±2.6 years) and 60 healthy males (mean age 20.7±2.6 years) as a con...

ea0056p319 | Clinical case reports - Thyroid/Others | ECE2018

Factitious hypoglycemia; Case report

Arikan Durmaz Senay , Gungunes Askin , Yalcin Selim

Introduction: Hypoglycemia is defined as a reduction in plasma glucose concentration to a level that may induce symptoms such as sweating, shaking, palpitation, headache, blurry vision, loss of consciousness, seizure, coma. We present a case with hypoglycemia which is due to the use of exogenous insulin.Case presentation: A 72-years-old patient with Alzheimer disease who was admitted to the emergency clinic because of unconscio...

ea0056p612 | Thyroid cancer | ECE2018

A case of diabetic patient with recurrent ketosis after U-300 glargine treatment

Ulasli Tugce , Gungunes Askin , Durmaz Senay Arikan

Introduction: U-300 glargine is a new generation long acting insulin. Nocturnal hypoglicemia and weight gain with U-300 glargine is lower than U-100 glargine. However, it may take 3–4 days for U-300 glargine to reach stable state in plasma. We report a diabetic case with recurrent ketosis after U-300 glargine.Case presentation: A 20 years old woman with type 1 diabetes mellitus who uses basal and bolus insulin (U-300 glargine and insülin aspart...

ea0041ep184 | Calcium and Vitamin D metabolism | ECE2016

Our cases of familial hypocalciuric hypercalcemia

Bayrak Muharrem , Cadirci Kenan , Carlioglu Ayse , Sevimli Hakan , Durmaz Senay

Familial hypocalciuric hypercalcemia is an inherited disease caused by inactivating heterozygous mutations in the gene encoding calcium-sensitive receptors, that affects calcium metabolism and generally follows a benign course. It must be also considered in the differential diagnosis of hyperparathyroidism. Six patients presenting to our internal diseases clinic between January, 2010, and June, 2015, were evaluated in terms of clinical and biochemical parameters. The youngest ...

ea0041ep238 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2016

Dyslipidemia in young women with polycystic ovary syndrome

Ayhan Mehmet Emin , Durmaz Senay Arikan , Carlioglu Ayse , Demirelli Selami

Introduction and aims: Polycystic ovary syndrome (PCOS) is a frequent endocrinopathy among with young women. It is known that insulin resistance is encountered in the vast majority of the women with PCOS and hence the risk of type 2 diabetes mellitus and coronary artery disease are increased. These cardiac and metabolic risk increments may also associated with hyperandrogenemia and dyslipidemia. The metabolic changes of lipid profiles in young women with PCOS are not completel...

ea0041ep645 | Endocrine tumours and neoplasia | ECE2016

Postprandial hypoglycemia in the presence of insulinoma – case report

Gungunes Askin , Arikan Durmaz Senay , Oguz Dilek , Rendeci Serkan

Background and aim: Although insulinoma typically causes fasting hypoglycemia, postprandial hypoglycemia occasionally reported in these patients. We aimed to report a rare case of insulinoma who atmitted to outpatient clinic with postprandial hypoglycemia.Case report: A 31-year-old woman was admitted to outpatient clinic with postprandial hypoglycemia. Capillary blood glucose levels were found 25 and 27 mg /dl during typical hypoglycemic symptoms such as...

ea0041ep907 | Pituitary - Clinical | ECE2016

Serum N-terminal pro brain natriuretic peptide level in patients with prolactinoma who were treated with caborgoline

Tasdelen Mustafa Rasid , Durmaz Senay Arikan , Yildirim Nesligul , Koc Eyup

Introduction and aim: Cabergoline, a long-lasting dopamine-agonist, is generally considered to be the safety drug for the treatment of prolactinoma. But, use of long time and high dose cabergoline may be a cause of cardiac valvulopathy in patient with prolactinoma. In present study, we aim to determine serum N-terminal probrain natriuretic peptide levels in patients with prolactinoma who were treated with cabergoline.Materials and methods: Thirty patient...

ea0037ep150 | Reproduction, endocrine disruptors and signalling | ECE2015

Serum N-terminal pro-B-type brain natriuretic peptide levels detection and cardiac interventricular septum tissue Doppler echocardiographic evaluation of women with polycystic ovary syndrome

Ayhan Mehmet Emin , Durmaz Senay Arikan , Carlioglu Ayse , Demirelli Selami

Introduction: The aim of this study, left ventricular systolic and diastolic function by echocardiography and tissue Doppler echocardiographic evaluation and relationship serum N-terminal pro-B-type brain natriuretic peptide (NT-proBNP) levels of women with polycystic ovary syndrome (PCOS).Materials and method: Thirty-two women with PCOS (age: 23.4–4.6 years; BMI: 23.8–4.8 kg/m2), similar age and BMI have features 30 healthy womens c...

ea0037ep946 | Thyroid (non-cancer) | ECE2015

Concomitant Graves' disease and primary hyperparathyroidism: case report

Cosar Ramazan , Sari Isilay Kalan , Durmaz Senay Arikan

Introduction: Hyperthyroidism is associated with asymptomatic hypercalcaemia due to increased calcium mobilization from bone and catecholamine metabolism. Hypercalcaemia secondary to hyperthyroidism coexist with decreased or normal parathyroid hormone level. We reported case of 30-year-old man who suffered from Graves’ disease and primary hyperparathyroidism.Case report: A 30-year-old male patient was admitted to our hospital suffered from palpitati...

ea0037ep1192 | Clinical Cases–Pituitary/Adrenal | ECE2015

Coexistence of ovary tumour, congenital adrenal hyperplasia and triple translocation involving chromosome 9,11 and 12: Initial steps of defining new syndrome?

Akbulut Sami , Durmaz Senay Arikan , Tuncali Timur , Sogutcu Nilgun

Introduction and aim: Congenital adrenal hyperplasia (CAH) is rare autosomal recessive disease. CAH due to 21-hydroxylase deficiency accounts for 95% of cases. We aim to define in this report 59-year-old woman with simple virilizing type CAH who diagnosed granulosa cell tumour and I172N mutation in the CYP21A as well as triple translocation involving chromosome 9p, 11p and 12p at first time in the literature.Case report: A 59-year-old woman was applied t...